Flash­ing red on RSV ma­ter­nal vac­cine, GSK paus­es PhI­II tri­al fol­low­ing ‘ob­ser­va­tion’ from safe­ty check

Glax­o­SmithK­line is halt­ing three tri­als of its ma­ter­nal RSV vac­cine can­di­date in­volv­ing preg­nant women, in­clud­ing a Phase III, in the wake of a safe­ty sig­nal.

A top late-stage as­set, the pro­gram has been spot­light­ed as a cen­tral fo­cus in GSK’s R&D case as it promis­es to de­liv­er a “step change” fol­low­ing the split of its con­sumer health­care unit. The phar­ma gi­ant had been ex­pect­ing a ma­ter­nal da­ta read­out in the sec­ond half of 2022.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER